

PART VI Summary of the risk management plan

This is a summary of the risk management plan (RMP) for CitraFleet. The RMP details important risks of CitraFleet, how these risks can be minimised, and how more information will be obtained about CitraFleet's risks and uncertainties.

CitraFleet's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how CitraFleet should be used.

Important new concerns or changes to the current ones will be included in updates of CitraFleet 's RMP.

I. The medicine and what it is used for

CitraFleet is authorised for Bowel cleansing prior to any diagnostic procedures requiring a clean bowel e.g., colonoscopy or x-ray examination. It contains Sodium picosulfate, Light magnesium oxide and Citric acid as the active substance and it is given orally (2 sachets administered separately according to the instructions provided in the SPC).

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of CitraFleet, together with measures to minimise such risks and the proposed studies for learning more about CitraFleet risks, are outlined below.

Measures to minimise the risks identified can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;

- Important advice on the medicine’s packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine’s legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.’

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of CitraFleet are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of CitraFleet. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g., on the long-term use of the medicine).

List of important risks and missing information		
Important risks	identified	None
Important risks	potential	None
Missing information		None

II.B Summary of important risks

Not applicable

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are not studies required for CitraFleet.